

Andrew L Hopkins

List of Publications by Citations

Source: <https://exaly.com/author-pdf/8127448/andrew-l-hopkins-publications-by-citations.pdf>
Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

43 papers	14,361 citations	29 h-index	47 g-index
47 ext. papers	16,281 ext. citations	16.5 avg, IF	7.04 L-index

#	Paper	IF	Citations
43	How many drug targets are there?. <i>Nature Reviews Drug Discovery</i> , 2006 , 5, 993-6	64.1	2624
42	The druggable genome. <i>Nature Reviews Drug Discovery</i> , 2002 , 1, 727-30	64.1	2427
41	Network pharmacology: the next paradigm in drug discovery. <i>Nature Chemical Biology</i> , 2008 , 4, 682-90	11.7	2255
40	Ligand efficiency: a useful metric for lead selection. <i>Drug Discovery Today</i> , 2004 , 9, 430-1	8.8	1500
39	Global mapping of pharmacological space. <i>Nature Biotechnology</i> , 2006 , 24, 805-15	44.5	686
38	Quantifying the chemical beauty of drugs. <i>Nature Chemistry</i> , 2012 , 4, 90-8	17.6	664
37	The role of ligand efficiency metrics in drug discovery. <i>Nature Reviews Drug Discovery</i> , 2014 , 13, 105-21	64.1	649
36	Network pharmacology. <i>Nature Biotechnology</i> , 2007 , 25, 1110-1	44.5	598
35	Automated design of ligands to polypharmacological profiles. <i>Nature</i> , 2012 , 492, 215-20	50.4	535
34	Can we rationally design promiscuous drugs?. <i>Current Opinion in Structural Biology</i> , 2006 , 16, 127-36	8.1	421
33	Complexes of HIV-1 reverse transcriptase with inhibitors of the HEPT series reveal conformational changes relevant to the design of potent non-nucleoside inhibitors. <i>Journal of Medicinal Chemistry</i> , 1996 , 39, 1589-600	8.3	326
32	Genomic-scale prioritization of drug targets: the TDR Targets database. <i>Nature Reviews Drug Discovery</i> , 2008 , 7, 900-7	64.1	244
31	Design of MKC-442 (emivirine) analogues with improved activity against drug-resistant HIV mutants. <i>Journal of Medicinal Chemistry</i> , 1999 , 42, 4500-5	8.3	124
30	Fragment screening by surface plasmon resonance. <i>ACS Medicinal Chemistry Letters</i> , 2010 , 1, 44-8	4.3	112
29	A crowdsourcing evaluation of the NIH chemical probes. <i>Nature Chemical Biology</i> , 2009 , 5, 441-7	11.7	97
28	Crystal structures of HIV-1 reverse transcriptase in complex with carboxanilide derivatives. <i>Biochemistry</i> , 1998 , 37, 14394-403	3.2	93
27	Validity of ligand efficiency metrics. <i>ACS Medicinal Chemistry Letters</i> , 2014 , 5, 616-8	4.3	85

26	Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 1. <i>Journal of Medicinal Chemistry</i> , 2004 , 47, 5912-22	8.3	79
25	Whole organism high-content screening by label-free, image-based Bayesian classification for parasitic diseases. <i>PLoS Neglected Tropical Diseases</i> , 2012 , 6, e1762	4.8	77
24	Screening for GPCR Ligands Using Surface Plasmon Resonance. <i>ACS Medicinal Chemistry Letters</i> , 2011 , 2, 549-554	4.3	68
23	3TAzido-3Tdeoxythymidine drug resistance mutations in HIV-1 reverse transcriptase can induce long range conformational changes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1998 , 95, 9518-23	11.5	67
22	Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 2. <i>Journal of Medicinal Chemistry</i> , 2004 , 47, 5923-36	8.3	58
21	Discovery of α Adrenergic Receptor Ligands Using Biosensor Fragment Screening of Tagged Wild-Type Receptor. <i>ACS Medicinal Chemistry Letters</i> , 2013 , 4, 1005-1010	4.3	55
20	The Joint European Compound Library: boosting precompetitive research. <i>Drug Discovery Today</i> , 2015 , 20, 181-6	8.8	55
19	Fragment screening by SPR and advanced application to GPCRs. <i>Progress in Biophysics and Molecular Biology</i> , 2014 , 116, 113-23	4.7	55
18	Emerging role of surface plasmon resonance in fragment-based drug discovery. <i>Future Medicinal Chemistry</i> , 2011 , 3, 1809-20	4.1	44
17	Mission possible. <i>Nature</i> , 2007 , 449, 166-9	50.4	41
16	Crystallographic analysis of the binding modes of thiazoloisoindolinone non-nucleoside inhibitors to HIV-1 reverse transcriptase and comparison with modeling studies. <i>Journal of Medicinal Chemistry</i> , 1999 , 42, 3845-51	8.3	38
15	Application of RNAi to Genomic Drug Target Validation in Schistosomes. <i>PLoS Neglected Tropical Diseases</i> , 2015 , 9, e0003801	4.8	24
14	An ontology for description of drug discovery investigations. <i>Journal of Integrative Bioinformatics</i> , 2010 , 7,	3.8	20
13	Surface plasmon resonance analysis of seven-transmembrane receptors. <i>Methods in Enzymology</i> , 2015 , 556, 499-525	1.7	19
12	Rapid analysis of pharmacology for infectious diseases. <i>Current Topics in Medicinal Chemistry</i> , 2011 , 11, 1292-300	3	15
11	Protein kinase drugs--optimism doesn't wait on facts. <i>Drug Discovery Today</i> , 2002 , 7, 801-2	8.8	14
10	Discovery of New Bromodomain Scaffolds by Biosensor Fragment Screening. <i>ACS Medicinal Chemistry Letters</i> , 2016 , 7, 1213-1218	4.3	14
9	An Ontology for Description of Drug Discovery Investigations. <i>Journal of Integrative Bioinformatics</i> , 2010 , 7,	3.8	11

8	Bispecific repurposed medicines targeting the viral and immunological arms of COVID-19. <i>Scientific Reports</i> , 2021 , 11, 13208	4.9	9
7	Structural bioinformatics in drug discovery. <i>Methods of Biochemical Analysis</i> , 2003 , 44, 477-97		8
6	Knowledge and Intelligence in Drug Design. <i>Annual Reports in Medicinal Chemistry</i> , 2006 , 425-437	1.6	6
5	Surveying GPCR solubilisation conditions using surface plasmon resonance. <i>Analytical Biochemistry</i> , 2018 , 556, 23-34	3.1	4
4	Pharmacological Space 2008 , 521-532		2
3	Introduction: The Case for Polypharmacology 2012 , 1-6		1
2	De Novo Design of Ligands against Multitarget Profiles 2013 , 287-309		
1	Pharmacological Space 2008 , 395-408		